Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBIT Margin: 2021-2025

Historic EBIT Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to -12.24%.

  • Tarsus Pharmaceuticals' EBIT Margin rose 4005.00% to -12.24% in Q3 2025 from the same period last year, while for Sep 2025 it was -23.88%, marking a year-over-year increase of 8459.00%. This contributed to the annual value of -65.90% for FY2024, which is 75463.00% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported EBIT Margin of -12.24% as of Q3 2025, which was up 43.36% from -21.61% recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' EBIT Margin ranged from a high of 4,027.12% in Q2 2023 and a low of -4,274.56% during Q4 2021.
  • For the 3-year period, Tarsus Pharmaceuticals' EBIT Margin averaged around 11.52%, with its median value being -52.29% (2024).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' EBIT Margin spiked by 488,517bps in 2022, and later crashed by 580,651bps in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' EBIT Margin (Quarterly) stood at -4,274.56% in 2021, then skyrocketed by 412,395bps to -150.61% in 2022, then crashed by 18,933bps to -339.94% in 2023, then spiked by 30,316bps to -36.77% in 2024, then soared by 4,005bps to -12.24% in 2025.
  • Its EBIT Margin stands at -12.24% for Q3 2025, versus -21.61% for Q2 2025 and -33.55% for Q1 2025.